Adagrasib Shows Anti-Tumor Activity in Heavily Pretreated KRAS-Mutant CRC

(MedPage Today) -- Adagrasib (Krazati) demonstrated antitumor activity in heavily pretreated patients with KRAS G12C-mutated, metastatic colorectal cancer (CRC), according to phase I/II study results. Monotherapy with the oral KRAS inhibitor led...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news